PneumoNP presentation Nanotherapeutics to treat antibiotic resistant Gram- negative respiratory infections.

Slides:

Advertisements

Similar presentations

European Social Fund A spotlight on EQUAL and active ageing.

Advertisements

Aleš Zupan. Importance of R&D and innovation activities for competitiveness of regions and national economies Role of state against the role of individual.

TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.

Prof. Vincent Rollet, Taiwan Health NCP Info Day, National Cheng Kung University 06 July 2012, Tainan, Taiwan EU FP7 at Glance & 2013 Health Working Program.

Making Innovation Affordable Jo Derbyshire European Commercial Manager

Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)

EIG – European Investor Gate Bridging the gap between public research funding and private investment.

MFG - Enabling Innovation with ICT and Media © MFG Baden-Württemberg | 1 Workshop B – ICT Innovation Vouchers: The Case of Baden-Württemberg Corinna Voss.

A European SRI Market Review London, November, 2012.

Antimicrobial resistance “One health fits all”

INTRODUCTION Course on Cleaner Production Middle East Technical University Department of Environmental Engineering Ankara 31 March 2008.

Health Stakeholder Consultation Event Frances Spillane, Assistant Secretary General Department of Health 11 March 2015.

Dutch Enterprise Policy: Topsector approach OECD CIIE-meeting, March 2015 Henry van der Wiel Ministry of Economic Affairs 26 March 2015.

SME Access to Finance & Enterprise Europe Network Georgia Tzenou, National Documentation Centre Enterprise Europe Network-Hellas.

ELMED European Logistics Mediterranean Ekaterinburg – February

Norway’s oil and gas industry Key figures 2005 (based on 2004 figures)

European Investment Fund Forum Binary Venture Capital Bucharest September 26.

Health Information Day, 22. November 2013 Enterprise Europe Network Martine DISS, Head of Unit, EACI and Hicham ABGHAY, Steinbeis-Europa-Zentrum, DE.

The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.

GATEWAY TO FINNISH EXPERTISE 1 Commercialization guidelines – NanoCom and ProNano results Dr. Eeva Viinikka, Business Director Programme Director of National.

BioRES Project: Sustainable Regional Supply Chains for Woody Bioenergy EU Horizon - Coordination and Support Action 1 BioRES has received funding from.

Copyright 2009 IDC. Reproduction is forbidden unless authorized. All rights reserved. Post Crisis: eSkills Are Needed to Drive Europe’s Innovation Society.

Hans Wolf-Watz, professor, UCMR, MIMS, Department of Microbiology, Umeå University, Sweden, Antibiotic resistance a new.

INNOWATER INNOWATER A Public-Private Innovation Partnership for Better Innovation Support Tools and Delivery Mechanisms in the Water Sector

Key Strategies for Improving Use of Existing and New Antibiotics -the European Experience Otto Cars Professor Inf. Diseases, Uppsala University, Sweden.

EUROPEAN COMMISSION DG Employment and Social Affairs National Employment and Social Inclusion Monitoring and ESF Operations II European Social Fund Regulation.

TOWER Towards sustainable Excellence by Innovating Regions.

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.

The Swedish Experience Otto Cars Prof. Infectious Diseases Uppsala University Hospital Sweden.

EU-South cooperation perspectives in eco- innovation Asel Doranova, Technopolis and Eco-innovation Observatory Geneva, 28 May 2013.

Funding Structures some ideas for designing innovative funding instruments Brigitte Hatvan.

Planned Commission Communication on the role of the Private Sector in Development A contribution to the reflexion on How to Innovate International Cooperation.

Bochum, June 2013 Luk Zelderloo Secretary General EASPD

1 JPI Water Partnership Towards Joint Programming in Research Water Challenges for a Changing World.

1 The role of Government in fostering competitiveness and growth Ken Warwick Deputy Chief Economic Adviser UK Department of Trade and Industry.

European Commission Introduction to the Community Programme for Employment and Social Solidarity PROGRESS

Energising Business Intelligence Funding Contacts.

CHAMP Physician Education is Essential in Improving Antibiotic Use in Primary Care: review of behavioural interventions Alike van der Velden Marijke Kuyvenhoven.

Training courses Presentation by JC Consultants Website :

1 SMEs – a priority for FP6 Barend Verachtert DG Research Unit B3 - Research and SMEs.

Rita Lečbychová European Commission Directorate-General for Research & Innovation.

Introduction to Marketing Bangor Transfer Abroad Programme Delivery of Values Delivery of Values – Being Close to the Customer.

Shaping tomorrow’s innovations today EUREKA EUREKA – Eurostars: a support to European innovation INNOVATION 2009 Prague, 1-3 December 200.

TRAFOON project is funded by the European Community's Seventh Framework Programme (FP7/ ) under grant agreement no Mrs. PATRICIA MORA GESTIONA.

RESTARTING EUROPEAN LONG-TERM INVESTMENT FINANCE Andrea Polo (UPF, Barcelona GSE) CEPR Financial Regulation Initiative London, 30 September 2015.

Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network

Enterprise Directorate General European Commission Kurt König Head of Unit “Communication and Awareness” Innovation Directorate

October 15, 2003 ITALIAN ICT MARKET OVERVIEW. october 15, 2003 ITALIAN ICT MARKET undersized in a european context Italy’s share = 9,2% vs. Germany’s.

Copyright (c) 2004 Elsevier Inc. All rights reserved. Basic Principles of Antimicrobial Therapy Chapter 79.

LSEC H2020-DS - & CIP Ulrich Seldeslachts, Brussels, January 27th, 2016.

“From GRID research to GRID business” Francesco Giglio

Impact of the inter-firm cooperation on company's performance: major changes during the economic crisis November 27, 2013 Oksana Kabakova.

EuropeAid Roberto Ridolfi Head of Unit. Central management of thematic budget lines/DCI and Food Facility - Europe Aid. Developing the regions of Africa.

Syria & Modern Banking in Light of Arab & International Practices Role of the Banking Sector in Developing Private Businesses Poul Gadegaard 2 nd - 3 rd.

Funding for Innovation Dr Deborah Pullen – Director, MBEKTN.

European Patients’ Academy on Therapeutic Innovation – The project is receiving support from the.

BioExcel - Intro Erwin Laure, KTH. PDC Center for High Performance Computing BioExcel Consortium KTH Royal Institute of Technology – Sweden University.

A Brief Introduction to The Energy Technology Partnership.

Publish Date : November 2016 No. of Pages : 205 Geography Coverage : Seven Countries Price for Single User Licence : USD 2000 Price.

Publish Date : December 2016 No. of Pages : 175 Geography Coverage : Five Countries Price for Single User Licence : USD 1500 Price.

European-Comparative Effectiveness Research on online Depression Treatment E-COMPARED is funded by the European Community’s Seventh Framework.

This project is co-funded by the European Union

International Energy Agency

LITHUANIAN RURAL PARLIAMENT April 24, 2015

Research Institutions

Welsh Health Innovation Technology Accelerator

Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.

Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.

SWEDISH INTERNATIONAL DEVELOPMENT COOPERATION AGENCY :

Presentation transcript:

PneumoNP presentation Nanotherapeutics to treat antibiotic resistant Gram- negative respiratory infections

PneumoNP presentation Introduction A European research project Nanotherapeutics to treat antibiotic resistant Gram-negative pneumonia infections Funded under the Seventh Framework Programme Collaborative project More than 5.5M€ Klebsiella pneumoniae as proof of concept

Objectives Project expected outcomes: a new inhablable drug composed of a nanotherapeutic system: an active antibacterial and a nanocarrier; a new aerosol technology specifically developed for the nanotherapeutic system; an innovative efficiency-efficacy test to follow-up the treatment; And a new diagnostic kit for the rapid and multiplex identification of bacteria causing respiratory infections. PneumoNP presentation

Work plan PneumoNP presentation

Partners PneumoNP presentation Research institutes Universities SMEs Entreprise Clinicians 11 partners 6 countries : Spain, Danemark, Germany, Italy, France, The Netherlands Each with a distinctive role

PneumoNP towards OI model PneumoNP presentation PneumoNP position in the nanomedicine value chain strenghtened by: 1.Good cooperation between all stakeholders 2.Integration of regulatory issues from the early stages of development 3.Awareness of scalability and GMP production

Economic impact Nanomedicine is a key component for pharma companies willing to maintain their competitiveness today. Expected market size (M€) Non-invasive delivery of protein nanomedicines010,000 ± 5,00020,000 ± 10,000 Non-invasive delivery of nucleic acid based nanomedicines 05,000 ± 2,00010,000 ± 5,000 PneumoNP presentation $63.8 billion 2010 $130.9 billion 2016 Expected growth of the nanomedicine market if research is correctly oriented and pushed forward Urgent need of MDR antibacterials and lack of new agents reaching the market..

Questions ? Find us PneumoNP presentation You can find out more about the PneumoNP project on our website. Follow us on Twitter to get the latest news, or on LinkedIn to share your expertise with PneumoNP ?